Prior Psychiatric Disorder and Post-Traumatic Stress, Depressive and Anxiety Disorder after Traumatic Brain Injury with Glasgow Coma Scale Score 13-15: A TRACK-TBI Study
Abstract
The most consistent risk factor for developing psychiatric problems post-traumatic brain injury (TBI) is a preexisting psychiatric disorder, but many studies have reported that psychiatric disorders can occur de novo following "mild" TBI. The objective of this secondary analysis of a prospective cohort study of patients (n = 1,947) with acute TBI and presenting Glasgow Coma Scale (GCS) score between 13 and 15 was to describe the association of pre-injury psychiatric history with prevalence and risk factors for probable posttraumatic stress disorder (PTSD), major depressive disorder (MDD), and nonspecific anxiety disorder (ANX) following TBI at long-term follow-up. Rates of probable PTSD, MDD, or ANX were analyzed from years 1 to 7 post-injury. Multivariable regression models were built to predict meeting cutoffs for PTSD, MDD, and ANX at 1 year, 2-4 years, and 5-7 years post-injury. Predictors were psychiatric history, migraine history, TBI history, initial head CT scan, loss of consciousness, post-traumatic amnesia, GCS, insurance type, highest level of care, cause of injury, years of education, age, sex, and race/ethnicity. Participants with history of pre-injury psychiatric disorder met clinical cutoffs for PTSD, MDD, and ANX at approximately double the rate of participants without history of psychiatric disorder at year 1 (16-28% vs. 5-13%), between years 2 and 4 (15-35% vs. 6-18%), and between years 5 and 7 (10-28% vs. 5-12%). Multivariable modeling confirmed several…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 1,947 participants or records.
Read the paper
Related studies
- Calcium Ions in the Physiology and Pathology of the Central Nervous System
- AI-powered in silico twins: redefining precision medicine through simulation, personalization, and predictive healthcare
- In silico functional, structural and pathogenicity analysis of missense single nucleotide polymorphisms in human MCM6 gene
- In Silico drug repurposing pipeline using deep learning and structure based approaches in epilepsy
- Targeting serotonin receptors with phytochemicals – an in-silico study
- In silico exploration of anti-prostate cancer compounds from differential expressed genes
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.